Assessment of Median and Mean Survival Time in Cancer Clinical Trials
Authors:
- 3 April 2023
- journal article
- letter
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 6 (4) , e236498
Abstract
Clinical trials often report the estimated median survival times to facilitate interpretation. However, the median makes limited use of the survival curve, focusing on the center to the exclusion of other information.1,2 Concerns exist about the median’s stability, as measured by the width of its CIs.3 In trials with few events or limited follow-up, the median survival may not be reached. In contrast, the restricted mean survival time (RMST) provides a clinically interpretable and global summary of survival and may be more stable than the median.3,4 The RMST represents a patient’s expected duration of survival over the follow-up period. For example, if the 5-year RMST of a treatment is 4 years, then a patient receiving that treatment would be expected to survive an average of 4 years over a 5-year follow-up period.Keywords
This publication has 6 references indexed in Scilit:
- Pitfall in the Design and Analysis of Comparative Oncology Trials With a Time-to-Event Endpoint and RecommendationsJNCI Cancer Spectrum, 2022
- Transparency in reporting of phase 3 cancer clinical trial resultsActa Oncologica, 2020
- Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?The Oncologist, 2019
- Interpretability of Cancer Clinical Trial Results Using Restricted Mean Survival Time as an Alternative to the Hazard RatioJAMA Oncology, 2017
- Moving Beyond the Hazard Ratio in Quantifying the Between-Group Difference in Survival AnalysisJournal of Clinical Oncology, 2014
- Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curvesBMC Medical Research Methodology, 2012